These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22395694)

  • 41. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 42. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.
    Nakamura KJ; Cerini C; Sobrera ER; Heath L; Sinkala M; Kankasa C; Thea DM; Mullins JI; Kuhn L; Aldrovandi GM
    AIDS; 2013 Jan; 27(3):337-46. PubMed ID: 23296195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
    Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The new vaccine challenges of "humanization" of HIV].
    Nau JY
    Rev Med Suisse; 2013 Aug; 9(394):1490-1. PubMed ID: 24024395
    [No Abstract]   [Full Text] [Related]  

  • 46. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Kelsoe G; Moody MA; Haynes BF
    Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New approaches to HIV vaccine development.
    Haynes BF
    Curr Opin Immunol; 2015 Aug; 35():39-47. PubMed ID: 26056742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.
    McCurley NP; Domi A; Basu R; Saunders KO; LaBranche CC; Montefiori DC; Haynes BF; Robinson HL
    PLoS One; 2017; 12(10):e0177863. PubMed ID: 29020058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
    Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV/AIDS: vaccines and alternate strategies for treatment and prevention.
    Voronin Y; Phogat S
    Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cape Town connections.
    Dumiak M
    IAVI Rep; 2014; 18(4):4-10. PubMed ID: 25625172
    [No Abstract]   [Full Text] [Related]  

  • 54. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
    van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model.
    Dzhivhuho GA; Rehrl SA; Ndlovu H; Horsnell WGC; Brombacher F; Williamson AL; Chege GK
    PLoS Pathog; 2018 Jul; 14(7):e1007182. PubMed ID: 30048550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
    Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody epitope exposure and neutralization of HIV-1.
    Pantophlet R
    Curr Pharm Des; 2010; 16(33):3729-43. PubMed ID: 21128886
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
    Montefiori DC; Mascola JR
    Curr Opin HIV AIDS; 2009 Sep; 4(5):347-51. PubMed ID: 20048696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-based vaccine design in HIV: blind men and the elephant?
    Pejchal R; Wilson IA
    Curr Pharm Des; 2010; 16(33):3744-53. PubMed ID: 21128885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth.
    van Schooten J; van Gils MJ
    Retrovirology; 2018 Nov; 15(1):74. PubMed ID: 30477581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.